Organon & Co. (NYSE:OGN) Hits New 1-Year Low Following Analyst Downgrade

Organon & Co. (NYSE:OGN) shares hit a new 52-week low during mid-day trading on Thursday after Morgan Stanley lowered their price target on the stock from $16.00 to $15.00. Morgan Stanley currently has an equal weight rating on the stock. Organon & Co. traded as low as $11.05 and last traded at $12.60, with a volume of 7089168 shares. The stock had previously closed at $11.65.

Several other research firms have also issued reports on OGN. Barclays lowered their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $20.60.

Institutional Trading of Organon & Co.

Several large investors have recently modified their holdings of OGN. Horizon Bancorp Inc. IN lifted its position in shares of Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after acquiring an additional 1,585 shares during the period. Millstone Evans Group LLC acquired a new position in shares of Organon & Co. during the fourth quarter valued at about $29,000. Larson Financial Group LLC boosted its position in shares of Organon & Co. by 345.4% during the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after purchasing an additional 1,734 shares in the last quarter. Riverview Trust Co boosted its position in shares of Organon & Co. by 117.7% during the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock worth $36,000 after purchasing an additional 1,292 shares in the last quarter. Finally, GeoWealth Management LLC acquired a new stake in shares of Organon & Co. in the 4th quarter valued at about $41,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Price Performance

The business has a 50-day moving average of $14.78 and a 200 day moving average of $15.78. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The firm has a market capitalization of $3.25 billion, a P/E ratio of 3.78, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. On average, sell-side analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 8.89%. Organon & Co.’s payout ratio is 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.